The global pharmacogenomics market size is calculated at USD 19.59 billion in 2025 and is forecasted to reach around USD 43.09 billion by 2034, accelerating at a CAGR of 9.17% from 2025 to 2034. The North America pharmacogenomics market size surpassed USD 7.53 billion in 2024 and is expanding at a CAGR of 9.20% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmacogenomics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmacogenomics Market, by Technology
8.1.1. DNA Sequencing
8.1.1.1. Market Revenue and Forecast
8.1.2. Microarray
8.1.2.1. Market Revenue and Forecast
8.1.3. Polymerase Chain Reaction
8.1.3.1. Market Revenue and Forecast
8.1.4. Electrophoresis
8.1.4.1. Market Revenue and Forecast
8.1.5. Mass Spectrometry
8.1.5.1. Market Revenue and Forecast
9.1. Pharmacogenomics Market, by Applications e
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast
9.1.2. Pain management
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurology
9.1.3.1. Market Revenue and Forecast
9.1.4. Oncology
9.1.4.1. Market Revenue and Forecast
9.1.5. Cardiovascular diseases
9.1.5.1. Market Revenue and Forecast
9.1.6. Infectious diseases
9.1.6.1. Market Revenue and Forecast
9.1.7. Psychiatry
9.1.7.1. Market Revenue and Forecast
9.1.8. Others
9.1.8.1. Market Revenue and Forecast
10.1. Pharmacogenomics Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Research institute
10.1.3.1. Market Revenue and Forecast
10.1.4. Medical, academic institute
10.1.4.1. Market Revenue and Forecast
11.1. Pharmacogenomics Market, by Distribution Channel
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast
11.1.2. Online Pharmacy
11.1.2.1. Market Revenue and Forecast
11.1.3. Retail Pharmacy
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology
12.1.2. Market Revenue and Forecast, by Applications
12.1.3. Market Revenue and Forecast, by End User
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology
12.1.5.2. Market Revenue and Forecast, by Applications
12.1.5.3. Market Revenue and Forecast, by End User
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology
12.1.6.2. Market Revenue and Forecast, by Applications
12.1.6.3. Market Revenue and Forecast, by End User
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology
12.2.2. Market Revenue and Forecast, by Applications
12.2.3. Market Revenue and Forecast, by End User
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology
12.2.5.2. Market Revenue and Forecast, by Applications
12.2.5.3. Market Revenue and Forecast, by End User
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology
12.2.6.2. Market Revenue and Forecast, by Applications
12.2.6.3. Market Revenue and Forecast, by End User
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology
12.2.7.2. Market Revenue and Forecast, by Applications
12.2.7.3. Market Revenue and Forecast, by End User
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology
12.2.8.2. Market Revenue and Forecast, by Applications
12.2.8.3. Market Revenue and Forecast, by End User
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology
12.3.2. Market Revenue and Forecast, by Applications
12.3.3. Market Revenue and Forecast, by End User
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology
12.3.5.2. Market Revenue and Forecast, by Applications
12.3.5.3. Market Revenue and Forecast, by End User
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology
12.3.6.2. Market Revenue and Forecast, by Applications
12.3.6.3. Market Revenue and Forecast, by End User
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology
12.3.7.2. Market Revenue and Forecast, by Applications
12.3.7.3. Market Revenue and Forecast, by End User
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology
12.3.8.2. Market Revenue and Forecast, by Applications
12.3.8.3. Market Revenue and Forecast, by End User
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology
12.4.2. Market Revenue and Forecast, by Applications
12.4.3. Market Revenue and Forecast, by End User
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology
12.4.5.2. Market Revenue and Forecast, by Applications
12.4.5.3. Market Revenue and Forecast, by End User
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology
12.4.6.2. Market Revenue and Forecast, by Applications
12.4.6.3. Market Revenue and Forecast, by End User
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology
12.4.7.2. Market Revenue and Forecast, by Applications
12.4.7.3. Market Revenue and Forecast, by End User
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology
12.4.8.2. Market Revenue and Forecast, by Applications
12.4.8.3. Market Revenue and Forecast, by End User
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology
12.5.2. Market Revenue and Forecast, by Applications
12.5.3. Market Revenue and Forecast, by End User
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology
12.5.5.2. Market Revenue and Forecast, by Applications
12.5.5.3. Market Revenue and Forecast, by End User
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology
12.5.6.2. Market Revenue and Forecast, by Applications
12.5.6.3. Market Revenue and Forecast, by End User
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Abbott (US)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bayer AG (Germany)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Allergan (Ireland)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. AbbVie Inc (US)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GmBH (Germany)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Teva Pharmaceutical Industries ltd (India)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Natco Pharma Limited (India)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lupin (India)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sun Pharmaceutical Industries ltd (India)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Merck & Co Inc (Germany)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample